# complicated urinary tract infections FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/complicated-urinary-tract-infections

> No upcoming FDA catalysts in complicated urinary tract infections; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for complicated urinary tract infections?

No upcoming FDA catalysts in complicated urinary tract infections; 3 past events are recorded. SEC Form 10-Q: "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." [Calendar and source filings](https://sec-api.dev/indications/complicated-urinary-tract-infections)

Source: SEC Form 10-Q, accession 0001193125-26-458593, https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/indications/complicated-urinary-tract-infections#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 19, 2025 | [Tebipenem NDA/BLA submission](https://sec-api.dev/pdufa/tebipenem) | SPRO | complicated urinary tract infections | completed | "On December 19, 2025, Spero Therapeutics, Inc. (the "Company") announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK"), filed a New Drug Application ("NDA") resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1701108/000119312525325821/d212013d8k.htm)) |
| Jun 2026 | [GSK plc FDA approval](https://sec-api.dev/companies/gsk/catalysts) | GSK | complicated urinary tract infections | completed, approved | "June 2026, the US FDA approved Utebzi for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426006949/a1493o.htm)) |
| June 17, 2026 | [Tebipenem FDA approval](https://sec-api.dev/pdufa/tebipenem) | SPRO | complicated urinary tract infections | completed, approved | "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm)) |

## Drugs

- [Tebipenem](https://sec-api.dev/pdufa/tebipenem) (SPRO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/complicated-urinary-tract-infections.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "complicated urinary tract infections FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/complicated-urinary-tract-infections

```bibtex
@misc{secapidev_indications_complicated_urinary_tract_infections_20261116,
  title        = {complicated urinary tract infections FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/complicated-urinary-tract-infections}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_complicated_urinary_tract_infections_20261116","title":"complicated urinary tract infections FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/complicated-urinary-tract-infections","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
